Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension

Diabetes, Obesity and Metabolism

Volumn 6, Issue 1, 2004, Pages 56-62

  Skurk, T ^a   Lee, Y M ^a   Nicuta Rolfs T O ^a   Haastert, B ^a   Wirth, A ^b   Hauner, Hans ^a,c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Teutoburger Wald Klinik   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiotensin II receptor antagonist; Candesartan; Fibrinolysis; Hypertension; PAI 1; t PA

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0742271966     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00316.x     Document Type: Article

References (34)

1. Landin K, Stigendal L, Eriksson E et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044-1048.
2. Juhan-Vague I & Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
3. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. On behalf of the ECAT Study Group: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-2063.
4. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes - a potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-110.
5. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
6. Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41: 65-71.
7. Cigolini M, Tonoli M, Borgato L et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-α? Atherosclerosis 1999; 143: 81-90.
8. Crandall DL, Quinet EM, Morgan GA, Busler DE, McHendry-Rinde B, Kral JG. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes. J Clin Endocrinol Metab 1999; 84: 3222-3227.
9. Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 4097-4105.
10. Gottschling-Zeller H, Birgel M, Röhrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 2000; 49: 666-671.
11. Yudkin JS, Coppack SW, Bulmer K, Rawesh A, Mohamed-Ali V. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. Thromb Res 1999; 96: 1-9.
12. Skurk T, Lee Y-M, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001; 37: 1336-1340.
13. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-1362.
14. Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and the enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998; 83: 3925-3929.
15. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999; 17: 555-560.
16. Schling P, Mallow M, Trindl A, Löffler G. Evidence for a local renin-angiotensin system in primary cultured human adipocytes. Int J Obes Relat Metab Disord 1999; 23: 336-341.
17. World Health Organization - International Society for Hypertension. Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-186.
18. Kluft C, Jie AF, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988; 59: 329-332.
19. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997; 79: 12-16.
20. Vaughan DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA. On behalf of the HEART Study Investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997; 96: 442-447.
21. Moriyama Y, Ogawa H, Oshima S et al. Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. Jpn Circ J 1997; 61: 308-314.
22. Pedersen OD, Gram J, Jeunemaitre X, Billaud E, Jespersen J. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction? Coron Artery Dis 1997; 8: 283-291.
23. Erdem Y, Usalan C, Haznedaroglu IC et al. Effects of an angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12: 1071-1076.
24. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and Ang II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 2001; 14: 921-926.
25. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241-246.
26. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285-290.
27. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985.
28. Fogari R, Zoppi A, Corradi L et al. Effect of different angiotensin II antagonists on fibrinolysis in hypertensive post-menopausal women. J Hypertens 2000; 18 (Suppl. 2): S155.
29. Folsom AR, Qamhieh DT, Wing RR et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb Vasc Biol 1993; 13: 162-169.
30. Velthuis-te Wierik EJ, Meijer P, Kluft C, van den Berg H. Beneficial effect of a moderately energy-restricted diet on fibrinoltyic factors in non-obese men. Metabolism 1995; 44: 1548-1552.
31. Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel BE. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr 1996; 64: 7-11.
32. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52: 329-333.
33. Mavri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 19: 1582-1587.
34. Mertens I & van Gaal LF. Obesity, haemostasis, and the fibrinolytic system. Obes Rev 2002; 3: 85-101.